Biohaven CEO Vlad Coric (Photo Credit_ Andrew Venditti)

Bio­haven shakes up lead­er­ship team as it feels the heat from mi­graine com­peti­tors

As Bio­haven Phar­ma comes off a roller­coast­er pipeline year, its CEO will take on more re­spon­si­bil­i­ty in a full C-suite makeover.

Matthew Buten

Vlad Coric was unan­i­mous­ly elect­ed to the role of chair­man of the board of di­rec­tors, af­ter De­clan Doogan’s re­tire­ment. Matthew Buten will take over the role of CFO af­ter James En­gel­hart’s re­tire­ment, and di­rec­tor Michael Hef­fer­nan has been ap­point­ed lead in­de­pen­dent di­rec­tor. All of the ap­point­ments are ef­fec­tive im­me­di­ate­ly, a com­pa­ny press re­lease said.

“The re­tire­ments de­scribed in this an­nounce­ment were not re­lat­ed to any dis­agree­ment with the com­pa­ny on any mat­ter re­lat­ing to the com­pa­ny’s op­er­a­tions, poli­cies or prac­tices,” per the re­lease.

The news comes on the same day that Bio­haven an­nounced that it will sub­mit a new drug ap­pli­ca­tion for in­tranasal za­veg­epant, a pain re­lief drug to treat mi­graines. That an­nounce­ment fol­lows the pos­i­tive re­sults from the sec­ond Phase III clin­i­cal tri­al, re­liev­ing par­tic­i­pants of the most both­er­some pain at the two-hour mark.

Pa­tients saw re­lief re­turn them to nor­mal func­tion as soon as 30 min­utes af­ter tak­ing za­veg­epant, Bio­haven not­ed at the time, and the pain-sus­pen­sion fac­tors last­ed be­tween two and 24 hours. If ap­proved, za­veg­epant will be the first in­tranasal cal­ci­tonin gene-re­lat­ed pep­tide avail­able to treat mi­graines in adults.

“The tri­al re­sults clear­ly show that the per­for­mance of this for­mu­la­tion ex­ceed­ed ex­pec­ta­tions by demon­strat­ing su­pe­ri­or­i­ty over place­bo on pain re­lief at 15 min­utes and re­turn to nor­mal func­tion by 30 min­utes,” Coric said in a state­ment. “The im­pres­sive ef­fi­ca­cy, safe­ty and tol­er­a­bil­i­ty pro­file shown in this tri­al high­lights the po­ten­tial of za­veg­epant to ush­er in a new era of non-oral CGRP tar­get­ing mi­graine ther­a­pies.”

Za­veg­epant beat place­bo in the end­point of pain free­dom 24% to 15%, and free­dom from the most both­er­some sys­tem by 40% vs 31%. Ab­nor­mal taste was the most com­mon side ef­fect, with 21% of tri­al par­tic­i­pants ex­pe­ri­enc­ing this, com­pared with 5% of those who were giv­en the place­bo.

Bio­haven is look­ing to re­bound af­ter turn­ing out a dud in its at­tempt to tar­get mul­ti­ple sys­tem at­ro­phy (MSA), a rare and fa­tal neu­rode­gen­er­a­tive dis­or­der. Its drug, verdiper­stat, failed to out­per­form the place­bo and whiffed on the pri­ma­ry ef­fi­ca­cy end­point, mark­ing the lat­est step in a tough year for the com­pa­ny af­ter it watched its Alzheimer’s study for glu­ta­mate mod­u­la­tor tro­r­ilu­zole crum­ble.

Last Jan­u­ary, it rolled out da­ta for tro­r­ilu­zole, a drug be­ing de­vel­oped for neu­rode­gen­er­a­tive dis­or­ders, that showed the can­di­date did not “sta­tis­ti­cal­ly dif­fer­en­ti­ate” it­self from a place­bo on the Alzheimer’s Dis­ease As­sess­ment Scale-Cog­ni­tive Sub­scale 11 (ADAS-cog) and the Clin­i­cal De­men­tia Rat­ing Scale Sum of Box­es (CDR-SB).

Even if Bio­haven gets za­veg­epant across the fin­ish line, it will face some com­pe­ti­tion. In May, Ab­b­Vie’s CGRP drug Ubrelvy got the go-ahead for acute treat­ment of mi­graine ahead of Bio­haven. Then in Sep­tem­ber, Ab­b­Vie’s oth­er oral CGRP re­cep­tor an­tag­o­nist Qulip­ta gained ap­proval.

As for Buten, he brings 20 years of ex­pe­ri­ence in health­care in­vest­ing to the team. He was pre­vi­ous­ly a port­fo­lio man­ag­er at Cat­a­pult/Mil­len­ni­um Part­ners and co-found­ed Sap­phire Cap­i­tal and Ar­gus Part­ners be­fore that.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

UP­DAT­ED: Pfiz­er fields a CRL for a $295M rare dis­ease play, giv­ing ri­val a big head start

Pfizer won’t be adding a new rare disease drug to the franchise club — for now, anyway.

The pharma giant put out word that their FDA application for the growth hormone therapy somatrogon got the regulatory heave-ho, though they didn’t even hint at a reason for the CRL. Following standard operating procedure, Pfizer said in a terse missive that they would be working with regulators on a followup.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Graphic: Alexander Lefterov for Endpoints News

Small biotechs with big drug am­bi­tions threat­en to up­end the tra­di­tion­al drug launch play­book

Of the countless decisions Vlad Coric had to make as Biohaven’s CEO over the past seven years, there was one that felt particularly nerve-wracking: Instead of selling to a Big Pharma, the company decided it would commercialize its migraine drug itself.

“I remember some investors yelling and pounding on the table like, you can’t do this. What are you thinking? You’re going to get crushed by AbbVie,” he recalled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

Pfizer debuted its first TV ad for its Prevnar 20 next-generation pneumococcal pneumonia vaccine. In the 60-second spot, several people (actor portrayals) with their ages listed as 65 or older are shown walking into a clinic as they turn to say they’re getting vaccinated with Prevnar 20 because they’re at risk.

The update to Pfizer’s blockbuster Prevnar 13 vaccine was approved in June, and as its name suggests is a vaccine for 20 serotypes — the original 13 plus seven more that cause pneumococcal disease. Pfizer used to spend heavily on TV ads to promote Prevnar 13 in 2018 and 2019 but cut back its TV budgets in the past two fall and winter seasonal spending cycles. Prevnar had been Pfizer’s top-selling drug, notching sales of just under $6 billion in 2020, and was the world’s top-selling vaccine before the Covid-19 vaccines came to market last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Alexander Lefterov/Endpoints News

A new can­cer im­munother­a­py brings cau­tious hope for a field long await­ing the next big break­through

Bob Seibert sat silent across from his daughter at their favorite Spanish restaurant near his home in Charleston County, SC, their paella growing cold as he read through all the places in his body doctors found tumors.

He had texted his wife, a pediatric intensive care nurse, when he got the alert that his online chart was ready. Although he saw immediately it was bad, many of the terms — peritoneal, right iliac — were inscrutable. But she was five hours downstate, at a loud group dinner the night before another daughter’s cheer competition.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roy Baynes, Merck

FDA bats back Mer­ck’s ‘pipeline in a prod­uct,’ de­mands more ef­fi­ca­cy da­ta

Despite some heavy blowback from analysts, Merck execs maintained an upbeat attitude about the market potential of its chronic cough drug gefapixant. But the confidence may be fading somewhat today as Merck puts out news that the FDA is handing back its application with a CRL.

Dubbed by Merck’s development chief Roy Baynes as a “pipeline in a product” with a variety of potential uses, Merck had fielded positive late-stage data demonstrating the drug’s ability to combat chronic cough. The drug dramatically reduced chronic cough in Phase III, but so did placebo, leaving Merck’s research team with a marginal success on the p-value side of the equation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Florida Gov. Ron DeSantis (AP Photo/Wilfredo Lee, File)

Opin­ion: Flori­da is so mAb crazy, Ron De­San­tis wants to use mAbs that don't work

Florida Gov. Ron DeSantis is trying so hard to politicize the FDA and demonize the federal government that he entered into an alternate universe on Monday evening in describing a recent FDA action to restrict the use of two monoclonal antibody, or mAb, treatments for Covid-19 that don’t work against Omicron.

Without further ado, let’s break down his statement from last night, line by line, adjective by adjective.

Not cheap­er by the dozen: Bris­tol My­ers be­comes the 12th phar­ma com­pa­ny to re­strict 340B sales

Bristol Myers Squibb recently joined 11 of its peer pharma companies in limiting how many contract pharmacies can access certain drugs discounted by a federal program known as 340B.

Bristol Myers is just the latest in a series of high-profile pharma companies moving in their own direction as the Biden administration’s Health Resources and Services Administration struggles to rein in the drug discount program for the neediest Americans.

Joaquin Duato, J&J CEO (Photo by Charles Sykes/Invision/AP)

New J&J CEO Joaquin Du­a­to promis­es an ag­gres­sive M&A hunt in quest to grow phar­ma sales

Joaquin Duato stepped away from the sideline and directly into the spotlight on Tuesday, delivering his first quarterly review for J&J as its newly-tapped CEO after an 11-year run in senior posts. And he had some mixed financial news to deliver today while laying claim to a string of blockbuster drugs in the making and outlining an appetite for small and medium-sized M&A deals.

Duato also didn’t exactly shun large buyouts when asked about the future of the company’s medtech business — where they look to be in either the top or number 2 position in every segment they’re in — even though the bar for getting those deals done is so much higher.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.

Amgen's Twitter campaign #DearAsthma inspired thousands of people to express struggles and frustrations with the disease

Am­gen’s #Dear­Asth­ma spon­sored tweet lands big on game day, spark­ing thou­sands to re­spond

Amgen wanted to know how people with asthma really felt about daily life with the disease. So it bought a promoted tweet on Twitter noting the not-so-simple realities of life with asthma and ended the post with a #DearAsthma hashtag, a megaphone emoji and a re-tweet button.

That was just over one week ago and the responses haven’t stopped. More than 7,000 posts so far on Twitter replied to #DearAsthma to detail struggles of daily life, expressing humor, frustration and sometimes anger. More than a few f-bombs have been typed or gif-ed in reply to communicate just how much many people “hate” the disease.